ArticleEJIFCC2026
Association of Hematological Inflammatory Indices with Glycemic Control in Type 2 Diabetes Mellitus- A Cross-sectional study.
Article in EJIFCC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Type 2 Diabetes Mellitus (T2DM) is a significant global health concern characterized by chronic low-grade inflammation, contributing to various complications. While Glycated Hemoglobin (HbA1c) is a primary tool for assessing glycemic control, hematological inflammatory indices derived from routine Complete Blood Count (CBC) are emerging as promising, low-cost indicators of systemic inflammation. This study aimed to investigate the association between these indices and glycemic control in T2DM patients. Methodology: This comparative cross-sectional study included 750 individuals, equally categorized into non-diabetic, well-controlled T2DM (HbA1c < 7%), and poorly controlled T2DM (HbA1c ≥ 7%) groups. HbA1c, and eleven hematological inflammatory indices like NLR, MLR, SII, SIRI, etc, were calculated and compared between the groups using JASP software followed by correlation, Receiver Operating Characteristic (ROC) curves, and binary logistic regression. Results: NLR, SII, SIRI, and AISI consistently showed a rising trend with poorer glycemic control, correlated moderately with HbA1c, and demonstrated moderate predictive performance for uncontrolled diabetes (AUC > 0.6). Subgroup analysis also revealed higher NLR in poorly controlled diabetics and regression analysis proved NLR as an independent predictor of poor glycemic control (adjusted odds ratio = 4.73, p < 0.001). Conclusion: This study demonstrates that hematological inflammatory indices, particularly NLR, SII, SIRI, and AISI, are significantly elevated in patients with poorly controlled T2DM, reflecting a state of chronic systemic inflammation. Among these, NLR shows the strongest and independent association with poor glycemic status, highlighting its potential as a low-cost, accessible adjunct marker for monitoring glycemic control and systemic inflammation in T2DM.
Indexed as
Identifiers
42006491PMC13088485What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.